IN2002DE00287A - - Google Patents

Download PDF

Info

Publication number
IN2002DE00287A
IN2002DE00287A IN287DE2002A IN2002DE00287A IN 2002DE00287 A IN2002DE00287 A IN 2002DE00287A IN 287DE2002 A IN287DE2002 A IN 287DE2002A IN 2002DE00287 A IN2002DE00287 A IN 2002DE00287A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Renato Morona
James Paton
Adrienne Paton
Original Assignee
Womens & Childrens Hospital
Luminis Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Womens & Childrens Hospital, Luminis Pty Ltd filed Critical Womens & Childrens Hospital
Publication of IN2002DE00287A publication Critical patent/IN2002DE00287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
IN287DE2002 1999-09-10 2002-03-08 IN2002DE00287A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ2757A AUPQ275799A0 (en) 1999-09-10 1999-09-10 Recombinant bacterium expressing an oligosaccharide receptor mimic

Publications (1)

Publication Number Publication Date
IN2002DE00287A true IN2002DE00287A (zh) 2007-03-02

Family

ID=3816927

Family Applications (1)

Application Number Title Priority Date Filing Date
IN287DE2002 IN2002DE00287A (zh) 1999-09-10 2002-03-08

Country Status (16)

Country Link
US (2) US6833130B1 (zh)
EP (1) EP1214396A4 (zh)
JP (1) JP2003514512A (zh)
AP (1) AP2002002444A0 (zh)
AU (1) AUPQ275799A0 (zh)
BR (1) BR0013915A (zh)
CA (1) CA2384081A1 (zh)
HU (1) HUP0202863A3 (zh)
IN (1) IN2002DE00287A (zh)
MX (1) MXPA02002536A (zh)
NZ (1) NZ517821A (zh)
OA (1) OA12020A (zh)
PL (1) PL364796A1 (zh)
SK (1) SK3472002A3 (zh)
WO (1) WO2001019960A1 (zh)
ZA (1) ZA200201958B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512730A (en) * 1998-12-04 2003-12-19 Univ Manitoba A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
WO2004003160A2 (en) * 2002-06-27 2004-01-08 University Of Washington Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
WO2004014417A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
WO2005089775A1 (en) * 2004-03-17 2005-09-29 Adelaide Research And Innovation Pty Ltd Treatment and prevention of enterotoxigenic escherichia coli diarrhoeas
JP4932699B2 (ja) * 2004-03-17 2012-05-16 グライコフィ， インコーポレイテッド 真菌および酵母におけるシチジンモノホスフェート−シアル酸合成経路を操作する方法
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
US8236538B2 (en) * 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
EP2265135B1 (en) * 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
EP2116139A1 (en) * 2008-05-08 2009-11-11 Nestec S.A. Sialic acid to support brain health in the elderly
CA2722127A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
JP2009288065A (ja) * 2008-05-29 2009-12-10 Keio Gijuku Ｓｈｉｇａｔｏｘｉｎ２ｅ及びＳｈｉｇａｔｏｘｉｎ２ｅに対する抗体の検出方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3485277A1 (en) * 2016-07-18 2019-05-22 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
CN106226536B (zh) * 2016-08-01 2017-11-10 福建省产品质量检验研究院 一种沙门氏菌h抗原的位相变异试验方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
US20230277607A1 (en) 2019-10-14 2023-09-07 Acaryon Gmbh Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof
WO2021263105A1 (en) * 2020-06-26 2021-12-30 University Of Massachusetts Anti-etec adhesin protein antibodies and methods of use
CN117377878A (zh) 2021-04-01 2024-01-09 贝克顿·迪金森公司 提高a族链球菌免疫测定特异性和灵敏度的方法
CN117004670B (zh) * 2023-10-07 2023-12-15 中国科学院天津工业生物技术研究所 一种磺基转移酶及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
US5089479A (en) 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
JP2636042B2 (ja) 1989-04-10 1997-07-30 株式会社三光開発科学研究所 ４，４▲′′′▼―ジヒドロキシクォーターフェニル誘導体およびその製造方法
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5595900A (en) 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
EP0553113B1 (en) * 1990-08-02 1998-11-25 Antex Biologics, Inc. Adhesion receptors for pathogenic or opportunistic microorganisms
US5260380A (en) 1992-01-23 1993-11-09 The University Of Akron Self-reinforced composite and process for preparing same
JP3041840B2 (ja) 1992-02-24 2000-05-15 東洋紡績株式会社 新規なグリセロールデヒドロゲナーゼ、その製法及びその用途
MX9304638A (es) 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US5401723A (en) 1992-12-02 1995-03-28 Colgate-Palmolive Company Glycoconjugate inhibition of Streptococcus pyrogenes adhesion
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
JPH07258093A (ja) 1994-03-23 1995-10-09 Morinaga Milk Ind Co Ltd 神経成長因子様剤
US5665561A (en) 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5627163A (en) 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
EP0839053A2 (en) 1995-07-14 1998-05-06 GlycoTech Corp. Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
US6069137A (en) 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
JP2997419B2 (ja) 1996-05-31 2000-01-11 雪印乳業株式会社 脳ガングリオシド含量減少抑制剤
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
JP4637976B2 (ja) 1996-07-17 2011-02-23 雪印乳業株式会社 腸内代謝改善剤
DE19640791A1 (de) 1996-10-02 1998-04-16 Syntesome Ges Fuer Medizinisch Glycokonjugate als Inhibitoren der viralen Zelladhäsion
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
WO2000070060A1 (en) * 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production of complex carbohydrates
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic

Also Published As

Publication number Publication date
SK3472002A3 (en) 2002-10-08
WO2001019960A1 (en) 2001-03-22
JP2003514512A (ja) 2003-04-22
EP1214396A4 (en) 2008-01-02
HUP0202863A2 (hu) 2002-12-28
OA12020A (en) 2006-04-19
PL364796A1 (en) 2004-12-13
NZ517821A (en) 2004-01-30
MXPA02002536A (es) 2003-07-21
AUPQ275799A0 (en) 1999-10-07
HUP0202863A3 (en) 2006-07-28
US6833130B1 (en) 2004-12-21
AP2002002444A0 (en) 2002-03-31
EP1214396A1 (en) 2002-06-19
BR0013915A (pt) 2002-11-19
CA2384081A1 (en) 2001-03-22
ZA200201958B (en) 2003-05-28
US20050250196A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
BE2018C020I2 (zh)
BE2016C007I2 (zh)
BE2015C057I2 (zh)
BE2015C018I2 (zh)
BE2014C017I2 (zh)
BE2013C051I2 (zh)
BE2013C020I2 (zh)
BE2013C015I2 (zh)
BE2013C001I2 (zh)
BE2012C036I2 (zh)
BE2011C004I2 (zh)
BE2010C011I2 (zh)
BE2008C046I2 (zh)
BE1025464I2 (zh)
JP2002503053A5 (zh)
BRPI0017527B8 (zh)
BE2008C047I2 (zh)
JP2002502024A5 (zh)
BRPI0001672A2 (zh)
BRPI0001542A2 (zh)
IN2002DE00287A (zh)
BRPI0012675B8 (zh)
BRPI0017522A2 (zh)
BRMU7902607U2 (zh)
CN3098146S (zh)